Dec 7, 2017
NCT03110562 : Phase 3 - Bortezomib, Selinexor, and Dexamethasone in Patients With Myeloma (BOSTON)
BOSTON Study This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and...
365
Dec 7, 2017
NCT03301220: Phase 3: A Study of Subcutaneous Daratumumab Versus Active Monitoring in HI Risk SMM
NCT03301220: Phase 3: A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple...
158
Dec 7, 2017
NCT03030261: Phase 2: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second ASCT RRMM
Multiple Myeloma Research Consortium NCT03030261: Phase 2: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous...
79
Dec 6, 2017
NCT03309111: Phase 1: ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With RRMM
NCT03309111: Phase 1: ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma Study of ISB 1342, a...
205
Dec 5, 2017
NCT03361748 : KarMMa - Phase 2 - To Determine the Efficacy and Safety of bb2121 in refractory MM
KarMMa bb2121 NCT03361748: Phase 2 - Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma...
544
Dec 5, 2017
NCT03215030: Phase 1/2: Safety, Tolerability, Efficacy, Pharmacok. Immunogenicity of TAK-573 in RRMM
Modakafusp alfa (Formerly TAK-573) NCT03215030: Phase 1/2: A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics,...
472
Dec 1, 2017
NCT03224507: Phase 2 - Monoclonal Antibody-Based Sequential Therapy for Deep Remission in MM -MASTER
MASTER TRIAL Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma (MASTER) Dara-KRd Monoclonal...
422
Dec 31, 2016
NCT02874742 : Phase 2 - Daratumumab, Len., Bortezomib & Dex (D-RVd) Vs (RVd) in New MM - GRIFFIN
The GRIFFIN trial Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and...
709
Dec 30, 2016
NCT02960555: Phase 2 - Isatuximab in Patients With High Risk Smoldering Plasma Cell Myeloma
Isatuximab in Treating Patients With High Risk Smoldering Plasma Cell Myeloma This phase II trial studies how well isatuximab works in...
275
Dec 30, 2016
NCT02659293: Phase 3 - ATLAS Trial: Carfilzomib, Lenalidomide & Dex Vs Lenalidomide Alone After ASCT
NCT02659293: Phase 3: ATLAS Trial: Carfilzomib, Lenalidomide and Dex Vs Lenalidomide Alone After ASCT KRd Vs R NDMM Trial of Carfilzomib,...
349
Dec 24, 2016
NCT01564537: Phase 3 - TOURMALINE-MM1 - Oral Ixazomib + Len/Dex Vs Placebo + Len/Dex RRMM
TOURMALINE-MM1 A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and...
323
Dec 23, 2016
NCT02755597: NCT02755597: Phase 3 - Venetoclax (ABT-199), Bortezomib and Dexamethasone in RRMM
Bellini RRMM A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as...
191
Dec 22, 2016
NCT02663518: Phase 1: A Trial of TTI-621 for Patients With Hematologic Malignancies and Solid tumors
NCT02663518: Phase 1: A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors NCT02663518: Phase 1: A...
39
Dec 20, 2016
NCT02963493: Phase 2 - Melphalan Flufenamide (Melflufen) With Dexamethasone in Relapsed MM (HORIZON)
HORIZON A Study of Melphalan Flufenamide (Melflufen) in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients...
208
Dec 17, 2016
NCT02671448: Pilot Trial of Homebound Stem Cell Transplantation
NCT02671448: Pilot Trial of Homebound Stem Cell Transplantation NCT02671448: Pilot Trial of Homebound Stem Cell Transplantation In this...
63
Dec 16, 2016
NCT02773030: Phase 1/2: CC-220 Monotherapy and in Combination With Treatments in NDMM / RRMM
CC-220-MM-001 NDMM Newly Diagnosed Multiple Myeloma RRMM Relapsed Refractory Multiple Myeloma A Study to Determine Dose, Safety,...
446
Dec 16, 2016
NCT02863991: Phase 1/2: Oral ONC201 in Relapsed/Refractory Multiple Myeloma
NCT02863991: Phase 1/2: Oral ONC201 in Relapsed/Refractory Multiple Myeloma ONC201 is an orally bioavailable first-in-class small...
57
Dec 16, 2016
NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM
NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory...
96
Dec 15, 2016
NCT02649790: Phase 1/2: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Cancer
RRMM Relapsed Refractory Multiple Myeloma NCT02649790: Phase 1/2: Study of the Safety, Tolerability and Efficacy of KPT-8602 in...
82